Monthly Archives - March 2020

Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the appointment of Pete Salzmann, M.D., MBA, to its Board of Directors. Dr. Salzmann brings 20 years of industry experience and currently serves as Chief Executive Officer of Immunovant (IMVT), a biopharmaceutical company focused on developing therapies for patients with autoimmune diseases. Read more >>

CORRECTING and REPLACING Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NLY01 for Patients with Parkinson’s Disease

All mentions of NLY01 have been corrected — Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the dosing of the first patient in its Phase 2 clinical trial of NLY01 for Parkinson’s disease. Read more >>

PlaceMe opens the first official co-living building in MA

PlaceMe, Boston’s pioneer co-living company, is launching the first official co-living building in Cambridge, MA. Starting April 1, 2020, the three-story building will accommodate 26 residents, offering all the benefits of the shared living concept: no-hassle moving, fully furnished units, a prime location at accessible rents which include utilities, wifi, and cleaning of shared areas, as well as dedicated community events.Read more >>